CYTK - Cytokinetics Inc Stock Price, Fair Value and News

61.05USD-1.48 (-2.37%)Delayed as of 30 Apr 2024, 12:13 pm ET

Market Summary

USD61.05-1.48

Delayedas of 30 Apr 2024, 12:13 pm

-2.37%

CYTK Alerts

2 major insider sales recently.

CYTK Stock Price

View Fullscreen

CYTK RSI Chart

CYTK Valuation

Market Cap

6.4B

Price/Earnings (Trailing)

-12.24

Price/Sales (Trailing)

855.36

EV/EBITDA

184.65

Price/Free Cashflow

-15.49

CYTK Price/Sales (Trailing)

CYTK Profitability

EBT Margin

40.39%

Return on Equity

136.22%

Return on Assets

-63.84%

Free Cashflow Yield

-6.45%

CYTK Fundamentals

CYTK Revenue

Revenue (TTM)

7.5M

Rev. Growth (Yr)

-14.56%

Rev. Growth (Qtr)

342.33%

CYTK Earnings

Earnings (TTM)

-526.3M

Earnings Growth (Yr)

0.33%

Earnings Growth (Qtr)

-5.79%

Breaking Down CYTK Revenue

52 Week Range

26.5562.22

(Low)(High)

Last 7 days

-5.7%

Last 30 days

-10.8%

Last 90 days

-20.6%

Trailing 12 Months

67.2%

How does CYTK drawdown profile look like?

CYTK Financial Health

Current Ratio

6.12

Debt/Equity

-0.15

Debt/Cashflow

-7.1

CYTK Investor Care

Shares Dilution (1Y)

8.24%

Diluted EPS (TTM)

-5.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	98.1M	10.0M	7.8M	7.5M
2022	76.5M	82.5M	88.5M	94.6M
2021	58.6M	57.8M	21.6M	70.4M
2020	22.2M	18.7M	54.3M	55.8M
2019	34.7M	35.6M	31.0M	26.9M
2018	17.9M	22.4M	27.0M	31.5M
2017	102.1M	99.4M	46.5M	13.4M
2016	32.7M	31.9M	83.0M	106.4M
2015	43.4M	42.1M	40.7M	28.7M
2014	37.8M	44.6M	49.5M	46.9M
2013	6.6M	5.7M	8.5M	30.6M
2012	5.1M	5.8M	6.1M	7.6M
2011	2.9M	3.3M	4.3M	4.0M
2010	0	55.2M	28.9M	2.6M
2009	0	0	0	81.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cytokinetics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 25, 2024	henderson john t	sold	-681,672	64.54	-10,562	-
Apr 12, 2024	malik fady ibraham	gifted	-	-	-150	evp research & development
Apr 09, 2024	malik fady ibraham	acquired	190,795	6.67	28,605	evp research & development
Apr 09, 2024	malik fady ibraham	sold	-2,422,920	74.3112	-32,605	evp research & development
Mar 14, 2024	callos andrew	acquired	-	-	16,941	evp, chief commercial officer
Mar 14, 2024	blum robert i	acquired	-	-	61,490	president & ceo
Mar 14, 2024	malik fady ibraham	acquired	-	-	42,666	evp research & development
Mar 14, 2024	wong robert	acquired	-	-	4,079	vp, chief accounting officer
Mar 06, 2024	wong robert	sold (taxes)	-57,316	66.88	-857	vp, chief accounting officer
Mar 06, 2024	blum robert i	sold (taxes)	-1,118,570	66.88	-16,725	president & ceo

Which funds bought or sold CYTK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 26, 2024	PEREGRINE CAPITAL MANAGEMENT LLC	reduced	-3.89	-2,118,690	8,861,410	0.25%
Apr 26, 2024	SECURIAN ASSET MANAGEMENT, INC	new	-	565,297	565,297	0.02%
Apr 26, 2024	PINNACLE ASSOCIATES LTD	reduced	-0.46	-3,540,330	18,030,000	0.28%
Apr 26, 2024	SAGE RHINO CAPITAL LLC	sold off	-100	-203,632	-	-%
Apr 26, 2024	UMB Bank, n.a.	added	6.96	-2,933	25,871	-%
Apr 26, 2024	YOUSIF CAPITAL MANAGEMENT, LLC	reduced	-7.15	-899,774	3,185,310	0.04%
Apr 26, 2024	First Horizon Advisors, Inc.	reduced	-6.77	-3,480	12,549	-%
Apr 26, 2024	Prestige Wealth Management Group LLC	unchanged	-	-121	631	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	12,501,000	12,501,000	0.01%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	reduced	-3.97	-325,451	1,355,790	-%

Are Funds Buying or Selling CYTK?

Are funds buying CYTK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CYTK

No. of Funds

CYTK Alerts

2 major insider sales recently.

Unveiling Cytokinetics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	11.24%	11,016,889	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	wellington management group llp	6.66%	6,530,884	SC 13G/A
Jan 25, 2024	state street corp	6.01%	5,893,358	SC 13G/A
Jan 22, 2024	blackrock inc.	16.4%	16,102,070	SC 13G/A
Feb 10, 2023	blackrock inc.	16.7%	15,767,874	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	10.64%	10,073,094	SC 13G/A
Feb 06, 2023	wellington management group llp	6.91%	6,542,724	SC 13G
Feb 03, 2023	state street corp	5.33%	5,044,914	SC 13G/A

Recent SEC filings of Cytokinetics Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	8-K	Current Report
Apr 25, 2024	144	Notice of Insider Sale Intent
Apr 25, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 09, 2024	144	Notice of Insider Sale Intent
Apr 09, 2024	4	Insider Trading
Apr 08, 2024	ARS	ARS
Apr 08, 2024	DEF 14A	DEF 14A
Apr 05, 2024	8-K	Current Report
Mar 18, 2024	4	Insider Trading

Peers (Alternatives to Cytokinetics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Cytokinetics Inc News

Latest updates

Cytokinetics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	342.3%	2.00	0.00	1.00	5.00	2.00	3.00	89.00	72.00	56.00	5.00	3.00	7.00	7.00	42.00	4.00	4.00	5.00	6.00	7.00	8.00	9.00
Operating Expenses	5.3%	129	123	123	129	129	111	100	79.00	77.00	75.00	58.00	47.00	43.00	37.00	36.00	34.00	29.00	30.00	34.00	33.00	31.00
S&GA Expenses	10.0%	44.00	40.00	40.00	50.00	54.00	48.00	43.00	33.00	34.00	26.00	21.00	16.00	14.00	12.00	14.00	12.00	11.00	10.00	10.00	9.00	7.00
R&D Expenses	3.0%	85.00	83.00	83.00	79.00	75.00	63.00	57.00	46.00	43.00	48.00	36.00	32.00	29.00	24.00	22.00	22.00	18.00	20.00	24.00	24.00	24.00
EBITDA Margin	16.7%	5.74*	4.92*	3.79*	0.34*	0.30*	0.28*	0.25*	0.28*	0.31*	0.99*	0.37*	-	-	-	-	-	-	-	-	-	-
Interest Expenses	0.4%	7.00	7.00	7.00	7.00	7.00	7.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	1.00	1.00	1.00	1.00
EBT Margin	3.8%	0.40*	0.39*	0.31*	0.03*	0.03*	0.03*	0.04*	0.04*	0.04*	0.14*	0.05*	-	-	-	-	-	-	-	-	-	-
Net Income	-5.8%	-136	-129	-128	-131	-137	-142	-19.82	-89.44	-30.57	-76.09	-61.55	-47.10	-43.93	-3.17	-40.78	-39.40	-30.64	-29.57	-32.11	-29.37	-26.47
Net Income Margin	-3.7%	-69.89*	-67.40*	-54.22*	-4.39*	-4.11*	-3.19*	-2.62*	-3.37*	-3.06*	-10.61*	-2.69*	-2.31*	-	-	-	-	-	-	-	-	-
Free Cashflow	23.1%	-74.11	-96.43	-122	-122	-101	-90.37	-91.33	-27.75	-62.49	-54.47	-38.29	-36.15	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	11.3%	824	741	780	890	1,015	1,076	772	856	841	828	564	577	534	474	232	257	290	187	198	199	211
Current Assets	11.9%	628	561	587	681	795	884	602	624	536	495	364	433	474	418	219	226	234	177	185	186	208
Cash Equivalents	13.4%	113	100	69.00	102	66.00	106	94.00	115	113	91.00	37.00	45.00	83.00	201	61.00	50.00	36.00	40.00	34.00	39.00	42.00
Net PPE	-9.1%	69.00	76.00	77.00	79.00	80.00	80.00	79.00	76.00	73.00	54.00	37.00	23.00	13.00	8.00	6.00	5.00	5.00	4.00	3.00	3.00	3.00
Liabilities	2.6%	1,211	1,179	1,113	1,119	1,123	1,092	660	740	597	579	548	509	420	325	311	302	301	207	203	195	185
Current Liabilities	32.1%	103	78.00	66.00	75.00	85.00	76.00	67.00	67.00	72.00	81.00	62.00	36.00	31.00	28.00	23.00	21.00	26.00	22.00	22.00	26.00	22.00
Long Term Debt	-4.1%	58.00	61.00	62.00	64.00	64.00	64.00	62.00	61.00	47.00	30.00	36.00	41.00	46.00	46.00	46.00	45.00	45.00	45.00	44.00	36.00	40.00
LT Debt, Current	-	10.00	-	-	-	1.00	-	-	-	-	17.00	11.00	6.00	-	-	-	-	-	-	-	6.00	3.00
LT Debt, Non Current	-4.1%	58.00	61.00	62.00	64.00	64.00	64.00	62.00	61.00	47.00	30.00	36.00	41.00	46.00	46.00	46.00	45.00	45.00	45.00	44.00	36.00	40.00
Shareholder's Equity	-Infinity%	-386	-	-	-	-107	-	111	116	244	249	16.00	68.00	113	150	-	-	-	-	-	3.00	26.00
Retained Earnings	-6.3%	-2,100	-1,975	-1,845	-1,700	-1,585	-1,448	-1,306	-1,286	-1,207	-1,177	-1,101	-1,039	-992	-948	-945	-904	-865	-834	-804	-772	-743
Additional Paid-In Capital	12.3%	1,726	1,537	1,514	1,490	1,482	1,438	1,422	1,406	1,452	1,426	1,117	1,107	1,105	1,097	866	857	853	814	799	775	769
Shares Outstanding	-	102	-	-	-	95.00	-	-	-	85.00	-	-	-	71.00	-	-	-	59.00	-	-	-	-
Float	-	-	-	2,000	-	-	-	2,000	-	-	-	1,443	-	-	-	1,413	-	-	-	653	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	23.0%	-74.03	-96.21	-121	-122	-98.19	-84.04	-90.47	-26.81	-44.74	-38.77	-29.50	-29.52	52.00	14.00	-27.44	-30.13	-19.05	-20.27	-24.68	-26.91	-12.33
Share Based Compensation	4.1%	19.00	19.00	19.00	15.00	13.00	13.00	12.00	9.00	7.00	8.00	7.00	5.00	5.00	5.00	5.00	4.00	3.00	3.00	3.00	2.00	-
Cashflow From Investing	-211.5%	-81.41	73.00	82.00	165	29.00	-292	65.00	-64.28	47.00	-208	19.00	-5.28	-173	-101	35.00	43.00	-105	14.00	-2.77	20.00	27.00
Cashflow From Financing	211.3%	169	54.00	5.00	-7.18	30.00	389	3.00	94.00	20.00	301	3.00	-3.60	4.00	226	4.00	-0.01	121	12.00	22.00	4.00	0.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CYTK Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 7,530	$ 94,588	$ 70,428
Operating expenses:
Research and development	330,123	240,813	159,938
General and administrative	173,612	177,977	96,803
Total operating expenses	503,735	418,790	256,741
Operating loss	(496,205)	(324,202)	(186,313)
Interest expense	(28,306)	(19,414)	(16,440)
Loss on extinguishment of debt	0	(24,939)	0
Non-cash interest expense on liabilities related to revenue participation right purchase agreements	(29,362)	(31,742)	(12,892)
Interest and other income, net	27,629	11,342	331
Net loss	$ (526,244)	$ (388,955)	$ (215,314)
Net loss per share - basic	$ (5.45)	$ (4.33)	$ (2.8)
Net loss per share - diluted	$ (5.45)	$ (4.33)	$ (2.8)
Weighted-average number of shares used in computing net loss per share - basic	96,524	89,825	76,886
Weighted-average number of shares used in computing net loss per share - diluted	96,524	89,825	76,886
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities, net	$ 3,600	$ (2,721)	$ (1,018)
Foreign currency translation adjustments	(20)	0	0
Comprehensive loss	(522,664)	(391,676)	(216,332)
Research and Development Revenues [Member]
Revenues:
Total revenues	4,030	6,588	10,572
License Revenues [Member]
Revenues:
Total revenues	0	0	54,856
Milestone Revenues [Member]
Revenues:
Total revenues	3,500	1,000	5,000
Realization of Revenue Participation Right Purchase Agreement [Member]
Revenues:
Total revenues	$ 0	$ 87,000	$ 0

CYTK Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 113,024	$ 65,582
Short-term investments	501,800	716,995
Accounts receivable	1,283	147
Prepaid expenses and other current assets	11,944	12,462
Total current assets	628,051	795,186
Long-term investments	40,534	46,708
Property and equipment, net	68,748	80,453
Operating lease right-of-use assets	78,987	82,737
Other assets	7,996	9,691
Total assets	824,316	1,014,775
Current liabilities:
Accounts payable	21,507	25,611
Accrued liabilities	42,641	44,096
Short-term operating lease liabilities	17,891	12,829
Current portion of long-term debt	10,080	958
Other current liabilities	10,559	1,123
Total current liabilities	102,678	84,617
Term loan, net	58,384	63,810
Convertible notes, net	548,989	545,808
Liabilities related to revenue participation right purchase agreements, net	379,975	300,501
Long-term operating lease liabilities	120,427	126,895
Other non-current liabilities	186	1,044
Total liabilities	1,210,639	1,122,675
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $0.001 par value: Authorized: 10,000,000 shares; Issued and outstanding: none	0	0
Common stock, $0.001 par value: Authorized: 163,000,000 shares; Issued and outstanding: 101,637,922 shares at December 31, 2023 and 94,833,975 shares at December 31, 2022	102	94
Additional paid-in capital	1,725,823	1,481,590
Accumulated other comprehensive loss	(10)	(3,590)
Accumulated deficit	(2,112,238)	(1,585,994)
Total stockholders' deficit	(386,323)	(107,900)
Total liabilities and stockholders' deficit	$ 824,316	$ 1,014,775

About Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CEO	Mr. Robert I. Blum
WEBSITE	cytokinetics.com
INDUSTRY	Biotechnology
EMPLOYEES	409

Cytokinetics Inc Frequently Asked Questions

What is the ticker symbol for Cytokinetics Inc? What does CYTK stand for in stocks?

CYTK is the stock ticker symbol of Cytokinetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cytokinetics Inc (CYTK)?

As of Mon Apr 29 2024, market cap of Cytokinetics Inc is 6.44 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CYTK stock?

You can check CYTK's fair value in chart for subscribers.

What is the fair value of CYTK stock?

You can check CYTK's fair value in chart for subscribers. The fair value of Cytokinetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cytokinetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CYTK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cytokinetics Inc a good stock to buy?

The fair value guage provides a quick view whether CYTK is over valued or under valued. Whether Cytokinetics Inc is cheap or expensive depends on the assumptions which impact Cytokinetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYTK.

What is Cytokinetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, CYTK's PE ratio (Price to Earnings) is -12.24 and Price to Sales (PS) ratio is 855.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYTK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cytokinetics Inc's stock?

In the past 10 years, Cytokinetics Inc has provided 0.302 (multiply by 100 for percentage) rate of return.